Therapeutic and diagnostic devices maker AngioDynamics (ANGO) has further broadened its VenaCure EVLT laser vein treatment with the worldwide launch of its VenaCure 1470 nanometer (nm) laser for treating varicose veins (abnormally swollen veins). This follows the New York-based company’s recent launch of the new 90 centimeter (cm) procedure kit for the VenaCure EVLT system.
Varicose veins afflict more than 40 million Americans annually and are more common in women than men. While varicose veins can occur in any part of the body, the veins that are more commonly affected are found in the legs.
The condition is characterized by symptoms such as pain, change in the color of the veins, itchiness and bulging of the veins. VenaCure EVLT is the most preferred endovenous laser treatment for varicose veins.
The VenaCure 1470nm laser, made in AngioDynamics’ Cambridge, U.K., facility, has been clinically shown to be highly effective in treating varicose veins as it uses a lower power output vis-à-vis other lasers to achieve excellent vein closure rates. The new long wavelength laser is complimented by the benefits of VenaCure’s NeverTouch gold-tip laser fiber. NeverTouch fiber improves patient comfort by mitigating post-operative pain and bruising while maximizing clinical efficacy.
VenaCure 1470nm laser’s light energy is more efficiently delivered through the NeverTouch fiber to the vein, and is more readily absorbed by the water in the blood and endothelial lining compared to short wavelength lasers, resulting in improved clinical outcome.
VenaCure EVLT, which includes DELTA series laser, procedure kits, accessories and a delivery system, offers patients a safe, minimally-invasive and effective option for treating the source of varicose veins while offering fast recovery. These lasers are now available in both 810 and 1470 wavelengths.
AngioDynamics develops and markets therapeutic and diagnostic devices to treat peripheral vascular disease (“PVD”) and other non-coronary diseases. The company has market leading positions in several of its operating segments including angiographic products and thrombolytic catheters. AngioDynamics competes with larger rivals such as Boston Scientific (BSX) and C.R. Bard (BCR).
AngioDynamics’ focus on interventional peripheral products is expected to help drive future growth. The company should continue to benefit from the ongoing shift from open surgery to less invasive interventional procedures.
However, we remain wary about the pricing and procedure volume headwinds, which continue to affect the company’s core vascular business. Currently, we have a Neutral recommendation on AngioDynamics.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
BARD C R INC (BCR): Free Stock Analysis Report
Be the first to comment